New RAS Inhibitor Daraxonrasib Beats Chemo in Metastatic Pancreatic Cancer
Phase 3 trial shows daraxonrasib significantly extends survival in previously treated pancreatic cancer patients.
20 articles
Phase 3 trial shows daraxonrasib significantly extends survival in previously treated pancreatic cancer patients.
Adding belzutifan to pembrolizumab improves disease-free survival in resected clear-cell renal-cell carcinoma, but toxicity rises sharply.
A KRAS-targeting drug earned a standing ovation at ASCO 2026 by doubling survival in one of cancer's deadliest forms.
A physician breaks down the expanding benefits of GLP-1 medications — from heart and kidney health to joints and cancer — and why tirzepatide wins.
Expert analysis reveals why NAD's anti-cancer benefits may outweigh potential risks despite ongoing scientific debate.
The MajesTEC-9 trial shows teclistamab significantly improves 18-month progression-free survival in relapsed multiple myeloma patients.
Major cardiovascular trial shows PCSK9 inhibitors prevent first heart attacks and strokes, plus new oral formulation makes treatment more accessible.
Retatrutide shows unprecedented weight loss results in phase 3 trials, but higher side effects may limit its advantage over existing medications.
Dr. Berg breaks down how statins deplete CoQ10, raise diabetes risk, and why addressing root causes of high cholesterol may matter more.
A Cleveland Clinic trial pitted rosuvastatin against six supplements. The drug won — but the supplement choices raise serious questions.
The REPLENISH phase 3 trial shows secukinumab plus a steroid taper drives higher remission rates in relapsed PMR than steroids alone.
Thomas DeLauer explains why L-serine may be more effective than vitamin C, NAC, and turmeric by boosting your body's natural antioxidant systems.
New research on 12,000+ adults reveals vitamin D's powerful brain protection, even for genetic risk carriers.
A short-form video by Max Lugavere suggesting a common drugstore drug may have cancer-prevention potential. Specific drug and evidence not available from metadata.
Research reveals how this ancient spice's unique amino acid helps regulate insulin naturally without dangerous blood sugar crashes.
A melanocortin-4 receptor agonist significantly reduced BMI and hunger in patients with acquired hypothalamic obesity over 52 weeks.
TARGET-D trial shows 52% reduction in repeat heart attacks when vitamin D levels are optimized above 40 ng/mL in cardiac patients.
First new COPD medication in over a decade targets dual pathways to improve breathing and reduce inflammation.
Phase 3 PROTEUS trial shows perioperative apalutamide combined with ADT significantly improves pathological response and 5-year metastasis-free survival.
Research-backed comparison of DEET, picaridin, and natural alternatives for mosquito protection and disease prevention.